N-(2-methylpropyl)-hydroxylamine | 64930-17-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-methylpropyl)-hydroxylamine
• 英文别名: 2-isobutylhydroxylamine；N-isobutylhydroxylamine；isobutylhydroxylamine；hydroxyisobutylamine；isobutylamino Alcohol；N-(2-methylpropyl)hydroxylamine
• CAS: 64930-17-2
• 化学式: C₄H₁₁NO
• 分子量: 89.1374
• InChiKey: NDCGVLJXFQKXOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(2-methylpropyl)-hydroxylamine 生成 异丙胺
  参考文献：
  名称：

  STOLYAROV B. V.; KRYLOV A. I., ZH. ORGAN. XIMII, 1980, 16, HO 9, 1802-1807

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲-1-硝丙烷 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 N-(2-methylpropyl)-hydroxylamine
  参考文献：
  名称：

  Stolyarov, B. V.; Krylov, A. I., Journal of Organic Chemistry USSR (English Translation), 1980, p. 1523 - 1528

  摘要：

  DOI：

文献信息

• Use of aryl nitrone compounds in methods for treating neuropathic pain
  申请人：——

  公开号：US20020165274A1

  公开（公告）日：2002-11-07

  3,4,5-trisubstituted aryl nitrone compounds having the formula: 1 where R 1 —R 4 are as defined in the specification are useful as therapeutics for neuropathic pain conditions in mammals.

  具有以下公式的3,4,5-三取代芳基亚硝基化合物：其中R1—R4如规范中定义的，对哺乳动物的神经病性疼痛症状具有治疗作用。
• 3,4,5-trisubstituted aryl nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation
  申请人：Centaur Pharmaceuticals, Inc.

  公开号：US06342523B1

  公开（公告）日：2002-01-29

  Disclosed are 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have the formula: where R1-R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

  揭示了3,4,5-三取代芳基亚硝基化合物及含有这种化合物的药物组合物。3,4,5-三取代芳基亚硝基化合物的化学式如下：其中R1-R4如规范中所定义。所披露的组合物可用作治疗哺乳动物炎症相关疾病，如关节炎，以及用作检测自由基的分析试剂。
• Design and Synthesis of 5-Lipoxygenase Inhibitors
  作者：Michael Strasser、Philip Cooper、Beatrice Dewald、Trevor Payne

  DOI：10.1002/hlca.19880710528

  日期：1988.8.10

  substrate specificity for 5-lipoxygenase and the known stereochemical course of the reaction, a hypothetical model of the enzyme active site was developed and used to design 2 types of selective inhibitors of 5-lipoxygenase. Both inhibitor types used aromatic rings in place of (Z)-olefins of the substrate and were designed to mimic the nonpolar end of arachidonic acid. One inhibitor type used a carboxylic-acid

  基于对5-脂氧合酶的底物特异性和已知的反应立体化学过程，开发了酶活性位点的假设模型，并用于设计两种类型的5-脂氧合酶的选择性抑制剂。两种抑制剂类型均使用芳族环代替底物的（Z）-烯烃，并被设计为模拟花生四烯酸的非极性末端。一种抑制剂类型与已知的环氧合酶抑制剂类似，使用羧酸与酶的O结合中心相互作用，而另一种抑制剂则采用羟胺功能与预计在酶活性位点的酪氨酸或半胱氨酸自由基相互作用。 。选择性5-脂氧合酶抑制剂是7-（己氧基）萘-2-乙酸（1）和N-甲基；-N（7-丙氧基萘-2-乙基）羟胺（2）。讨论了两种抑制剂的构效关系。
• Imidazonaphthyridines
  申请人：3M Innovative Properties Company

  公开号：US06194425B1

  公开（公告）日：2001-02-27

  Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.

  咪唑并噻吩并噻吩衍生物和四氢咪唑并噻吩衍生物诱导细胞因子的生物合成，例如干扰素和肿瘤坏死因子。这些化合物具有抗病毒和抗肿瘤特性。还公开了制备这些化合物以及在制备这些化合物中有用的中间体的方法。
• 3,4,5-Trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
  申请人：RENOVIS, INC.

  公开号：US20040198835A1

  公开（公告）日：2004-10-07

  Disclosed are 3,4,5-trisubstituted aryl nitrone compoundsd and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R 1 -R 4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

  本发明涉及3,4,5-三取代基芳基亚硝基化合物及含有此类化合物的医药组合物。3,4,5-三取代基芳基亚硝基化合物的化学式为(I)，其中R1-R4如规范中定义。所述组合物可用于哺乳动物的与炎症相关的疾病，例如关节炎等治疗，并可作为检测自由基的分析试剂。